TaperDex 6-day (dexamethasone) NDC 71205-012

NDC codes

FDA NDC Directory

Product NDC (as listed)71205-012Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71205-0012Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71205-012-21	71205001221	1 BLISTER PACK in 1 CARTON (71205-012-21) / 21 TABLET in 1 BLISTER PACKMarketed from Apr 2, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): TaperDex 6-day
Generic name (nonproprietary): dexamethasone
Active ingredients: Dexamethasone — 1.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Proficient Rx LP
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 088237
Marketing start: Jan 19, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 71205-012_9c466480-174a-4ddc-a720-76e5d3911f01SPL ID 9c466480-174a-4ddc-a720-76e5d3911f01SPL set ID a0d298f3-6ba6-45a5-81bf-82a3ad93d0a9RxCUI 197580, 846192, 1998482UNII 7S5I7G3JQL
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471205001221 followed by a unit qualifier and the quantity

Package 71205-0012-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 1, 2020.

Indications (excerpt from the label)

INDICATIONS AND USAGE Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocort…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 088237

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 088237
Product	Strength	Form · route	Labeler	Product NDC
TaperDex 12-daydexamethasone	Dexamethasone 1.5 mg/1	TabletOral	Proficient Rx LP	71205-013